METROPOLIS - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 3.3
| Stock Code | METROPOLIS | Market Cap | 9,728 Cr. | Current Price | 1,876 ₹ | High / Low | 2,263 ₹ |
| Stock P/E | 67.5 | Book Value | 256 ₹ | Dividend Yield | 0.05 % | ROCE | 13.4 % |
| ROE | 10.5 % | Face Value | 2.00 ₹ | DMA 50 | 1,886 ₹ | DMA 200 | 1,912 ₹ |
| Chg in FII Hold | -0.84 % | Chg in DII Hold | 1.63 % | PAT Qtr | 38.0 Cr. | PAT Prev Qtr | 46.6 Cr. |
| RSI | 50.4 | MACD | -19.7 | Volume | 85,273 | Avg Vol 1Wk | 79,508 |
| Low price | 1,315 ₹ | High price | 2,263 ₹ | PEG Ratio | -4.83 | Debt to equity | 0.11 |
| 52w Index | 59.2 % | Qtr Profit Var | 38.9 % | EPS | 26.6 ₹ | Industry PE | 32.6 |
📊 Analysis: Metropolis shows weak-to-moderate momentum for intraday trading today. RSI at 50.4 indicates neutral conditions, while MACD is negative (-19.7), suggesting short-term weakness. Current price (1,876 ₹) is slightly below both 50 DMA (1,886 ₹) and 200 DMA (1,912 ₹), showing short-term and medium-term weakness. Volume is slightly above the 1-week average, indicating active participation but without strong bullish conviction.
💡 Optimal Buy Price: Around 1,870–1,880 ₹ if intraday support holds.
🎯 Profit Exit Levels: 1,895 ₹ (first target), 1,915 ₹ (second target if momentum improves).
⚠️ Stop-Loss: 1,860 ₹ to protect against downside risk.
📌 If Already Holding: Consider exiting near 1,895–1,915 ₹ if momentum indicators remain weak. If price falls below 1,860 ₹ with volume confirmation, exit to avoid deeper losses.
✅ Positive
- Quarterly PAT growth (38 Cr. vs 46.6 Cr. previous quarter, though sequential decline).
- EPS at 26.6 ₹ supports earnings visibility.
- ROCE (13.4%) and ROE (10.5%) indicate moderate capital efficiency.
- DII holdings increased (+1.63%), showing strong domestic support.
- Debt-to-equity ratio at 0.11, low leverage.
⚠️ Limitation
- Price trading below both 50 DMA and 200 DMA, showing weakness.
- RSI and MACD indicate bearish momentum.
- PEG ratio at -4.83 indicates poor valuation relative to growth.
- Dividend yield at 0.05% is very low, limiting income appeal.
📉 Company Negative News
- FII holdings decreased (-0.84%), showing reduced foreign confidence.
- Sequential PAT decline compared to previous quarter.
- 52-week index at 59.2% shows underperformance relative to highs.
📈 Company Positive News
- DII holdings increased significantly (+1.63%), showing domestic investor confidence.
- Quarterly profit variation of 38.9% shows operational improvement year-on-year.
🏭 Industry
- Diagnostics and healthcare services sector trading at PE ~32.6, Metropolis is overvalued with P/E of 67.5.
- Sector demand remains defensive, benefiting from rising healthcare awareness and diagnostic expansion.
🔎 Conclusion
Metropolis is a weak intraday candidate today due to bearish technicals and overvaluation. A cautious buy near 1,870–1,880 ₹ with targets at 1,895 ₹ and 1,915 ₹ offers limited opportunity, but traders should maintain a strict stop-loss at 1,860 ₹. Better suited for swing trades if price sustains above 1,886 ₹ (50 DMA) with improving momentum.
Would you like me to prepare a peer benchmarking overlay with other diagnostic and healthcare service companies (like Dr. Lal PathLabs, Thyrocare, Vijaya Diagnostic) so you can compare Metropolis’s intraday strength against sector peers?